These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 33121411)

  • 1. The Potentials of Uncariae Ramulus Cum Uncis for the Treatment of Migraine: Targeting CGRP in the Trigeminovascular System.
    Chong CM; Zhong Z; Vong CT; Wang S; Lu JJ; Zhong HJ; Su H; Wang Y
    Curr Neuropharmacol; 2021; 19(7):1090-1100. PubMed ID: 33121411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Tianma (Rhizoma Gastrodiae) and Gouteng (Ramulus Uncariae Rhynchophyllae cum Uncis) on cytochrome P450 enzyme activities in rats.
    Liu X; Wang X; Peng Y; Wang X
    J Tradit Chin Med; 2021 Apr; 41(2):284-292. PubMed ID: 33825409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Advance in studies on neuroprotective mechanism of Uncariae Ramulus Cum Uncis].
    Wei FF; Zeng CQ; Zhao YH; Liu L
    Zhongguo Zhong Yao Za Zhi; 2014 Jul; 39(14):2603-7. PubMed ID: 25272481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention.
    Schoenen J; Manise M; Nonis R; Gérard P; Timmermans G
    Rev Neurol (Paris); 2020 Dec; 176(10):788-803. PubMed ID: 32758365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new era for migraine: The role of calcitonin gene-related peptide in the trigeminovascular system.
    Chen ST; Wu JW
    Prog Brain Res; 2020; 255():123-142. PubMed ID: 33008504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Advances in indole alkaloids from traditional Chinese medicine of Uncariae Ramulus Cum Uncis documented in Chinese Pharmacopoeia].
    Zhang JG; Chen JJ; Geng CA
    Zhongguo Zhong Yao Za Zhi; 2019 Feb; 44(4):685-695. PubMed ID: 30989880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Application of CGRP-Related Monoclonal Antibodies in Migraine Management].
    Shibata M
    Brain Nerve; 2021 Apr; 73(4):327-337. PubMed ID: 33824220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in targeting calcitonin gene-related peptide for the treatment of menstrual migraine: A narrative review.
    Jiang Y; Huang ZL
    Medicine (Baltimore); 2022 Jun; 101(24):e29361. PubMed ID: 35713436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Discovery and study on potential effect of herbal pair of Uncariae Ramulus cum Uncis-Eucommiae Cortex on pregnancy hypertension based on network pharmacology and molecular docking].
    Na Z; Zi-Jun S; Jian-Wu HE; Cai-Feng LI; Feng-Rong Z; Jun-Qi W; Xiu-Lan H; Zhi-Yong LI
    Zhongguo Zhong Yao Za Zhi; 2020 Nov; 45(22):5393-5402. PubMed ID: 33350198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting of calcitonin gene-related peptide action as a new strategy for migraine treatment.
    Kuzawińska O; Lis K; Cessak G; Mirowska-Guzel D; Bałkowiec-Iskra E
    Neurol Neurochir Pol; 2016; 50(6):463-467. PubMed ID: 27553188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective Inhibition of Trigeminovascular Neurons by Fremanezumab: A Humanized Monoclonal Anti-CGRP Antibody.
    Melo-Carrillo A; Noseda R; Nir RR; Schain AJ; Stratton J; Strassman AM; Burstein R
    J Neurosci; 2017 Jul; 37(30):7149-7163. PubMed ID: 28642283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans.
    de Vries T; Villalón CM; MaassenVanDenBrink A
    Pharmacol Ther; 2020 Jul; 211():107528. PubMed ID: 32173558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
    Tepper SJ
    Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calcitonin gene-related peptide (CGRP) and migraine current understanding and state of development.
    Bigal ME; Walter S; Rapoport AM
    Headache; 2013 Sep; 53(8):1230-44. PubMed ID: 23848260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CGRP as the target of new migraine therapies - successful translation from bench to clinic.
    Edvinsson L; Haanes KA; Warfvinge K; Krause DN
    Nat Rev Neurol; 2018 Jun; 14(6):338-350. PubMed ID: 29691490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcitonin Gene-Related Peptide Antagonists in the Treatment of Episodic Migraine.
    Yuan H; White CS; Silberstein SD
    Clin Pharmacol Ther; 2019 May; 105(5):1121-1129. PubMed ID: 30648737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Wiping Out CGRP: Potential Cardiovascular Risks.
    MaassenVanDenBrink A; Meijer J; Villalón CM; Ferrari MD
    Trends Pharmacol Sci; 2016 Sep; 37(9):779-788. PubMed ID: 27338837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calcitonin gene-related peptide (CGRP): role in migraine pathophysiology and therapeutic targeting.
    Wattiez AS; Sowers LP; Russo AF
    Expert Opin Ther Targets; 2020 Feb; 24(2):91-100. PubMed ID: 32003253
    [No Abstract]   [Full Text] [Related]  

  • 19. Inflammatory complications of CGRP monoclonal antibodies: a case series.
    Ray JC; Allen P; Bacsi A; Bosco JJ; Chen L; Eller M; Kua H; Lim LL; Matharu MS; Monif M; Ruttledge M; Stark RJ; Hutton EJ
    J Headache Pain; 2021 Oct; 22(1):121. PubMed ID: 34625019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal antibodies for migraine: preventing calcitonin gene-related peptide activity.
    Bigal ME; Walter S
    CNS Drugs; 2014 May; 28(5):389-99. PubMed ID: 24638916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.